News

Medical Device Network on MSN3d
Novocure’s device for metastatic NSCLC treatment gains CE Mark
The data from the Phase III LUNAR trial, which assessed the device’s treatment efficacy and safety, supported the approval.
Business Wire4d
Novocure’s Optune Lua® Receives CE Mark Approval for the Treatment of Metastatic Non-Small Cell Lung Cancer
“The CE Mark approval for Optune Lua for metastatic non-small cell lung cancer is a significant milestone in Novocure’s efforts to improve outcomes for people living with aggressive cancers ...
Seeking Alpha25d
Zimmer Biomet granted CE Mark for RibFix Advantage Fixation System
Zimmer Biomet (NYSE:ZBH) announced Tuesday that the EU regulators granted CE Mark certification for the company’s RibFix Advantage Fixation System, designed as a less invasive approach to rib ...